💊 SGLT2i vs GLP-1 in Lupus Nephritis TriNetX evaluating the impact of GLP-1 agonists vs SGLT-2 inhibitors on outcomes of lupus nephritis 📊 GLP-1 use linked to better renal & CV outcomes in LN including: ⬇️ CKD progression ⬇️ Mortality ⬇️ Acute MI @RheumNow #ACR25 https://t.co/v4LgKFDt68

Could a sputum test predict risk for RA conversion in at-risk patients? 98 at risk pts, Converters had higher -BL sputum CCP levels -BL Sputum nucleosome and cit-nucleosome levels !although not asso after adjusting for sputum anti-CCP-IgA level In converters, correlation of https://t.co/bqmQqS1Jz5

Where do patients find informations about their RMD? Study of 705pts -80% search engines via smartphone 80.3% Different pattern within 2 yrs of diagnosis vs. later stage: -more frequent 19% vs 8% Most users find online content -understandable 80% -apply it in daily life 68% https://t.co/9IMvpt2ffr

More biomarkers predictive of conversion to clinical RA in at-risk pts Serum PAD4 & PAD 4 levels measured in CCP+ at-risk individuals -PAD4 (not PAD2) increased in RA Converters vs. non converters and HC -PAD4 levels Pre-RA = RA Within high CCP+ at risk individuals, higher https://t.co/LU5zUzui1G

Trying to reach RA, PsA patients on social media, to participate in studies? Simple, informational messages work for recruitment Message framing affects engagement but not recruitment The more we understand, the better we can reach the right people #ACR25 ABST0187 @RheumNow https://t.co/JoAthXhXvi

A simple flow cytometry analysis of peripheral blood monocytes to predicts progression to clinical RA or PsA in at-risk patients? Too good to be true! 284 RA 56 PsA 57 HC -HLA-DR higher in PsA -CD11c lower in RA But no clear difference between Converters and non Converters https://t.co/f3Sett4eXd

Rheumatologists love AI scribes in clinic. The way we interact is potentially well suited, and accuracy and synthesis quality is bound to improve. Is it inevitable that it will universally be standard practice for us soon? UCSF clinics #ACR25 @JYazdanyMD ABST0189 @RheumNow https://t.co/kOzfpLlvgD

CMV is a worry with high-dose steroids, especially in certain settings. The risk is far from universal, though: in this Korean cohort treated with high dose pred, almost no-one without risk factors got it. Meds are rarely the only infection risk factor #ACR25 ABST203 @RheumNow https://t.co/zLYhLVKgYL

#ACR25 Abstr#803 We need more data to justify biologics before conventional immunosuppressant in #SLE. Post-hoc analysis of 5 Phase 3 RCTs = improved efficacy & GC reduction in BEL+No IS vs PBO+IS. Potential selection bias as control group might be doomed to fail @RheumNow https://t.co/kXmrOUbJzj

#0794 LLMs can accelerate qualitative lupus pregnancy research. Using AI to translate & analyze interviews from Portuguese, GPT-4 achieved top accuracy & coherence vs human themes. LLMs may expand inclusion & equity in rheum research. @RheumNow #ACR25 https://t.co/TAxg6Qyk0L

Real-world Indian cohort of 290 axSpA patients, generic tofacitinib achieved low/inactive disease in 89% after 25 months. Most adverse events were mild (e.g., transaminitis 14.5%) and manageable. No serious infections or MACE reported. A cost-effective alternative to bDMARDs in https://t.co/JBHfNq7kYt